Related Experiment Video
Updated: May 25, 2025
A Silver Nanoparticle Method for Ameliorating Biliary Atresia Syndrome in Mice
Published on: October 13, 2018
Engineered Exosomes Carrying Super-Repressor IκB Reduced Biliary Atresia-Induced Liver Fibrosis in Minipig and Mouse
Jisoo Kang1, Cheolhyoung Park2, Hanoul Yun2
1College of Pharmacy, Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Republic of Korea.
Insights
Exosome therapy (Exo-SrIκB) successfully treated liver fibrosis in animal models by inhibiting Nuclear Factor-kappa B (NF-κB) signaling, offering a promising approach for chronic liver diseases.
Area of Science:
- Hepatology
- Biotechnology
- Nanomedicine
Background:
- Biliary atresia causes progressive liver damage, including fibrosis, with unclear pathogenesis.
- Nuclear Factor-kappa B (NF-κB) is a key mediator in liver inflammation and fibrosis.
- Exosome-based therapies offer targeted delivery and low immunogenicity for liver diseases.
Purpose of the Study:
- To evaluate the therapeutic potential of Exo-SrIκB for cholestatic liver fibrosis.
- To assess the efficacy of exosome-encapsulated super-repressor IκB (SrIκB) in preclinical models.
Main Methods:
- Exo-SrIκB was engineered using EXPLOR technology to load SrIκB into exosomes.
- Therapeutic efficacy was tested in minipig and mouse models of induced cholestatic liver disease.
Main Results:
- Exo-SrIκB significantly reduced liver fibrosis progression in both models.
- Inhibition of NF-κB nuclear translocation and reduced fibrotic markers (collagen, α-SMA) were observed.
- Improved hepatic function was noted in treated animals compared to controls.
Conclusions:
- Exo-SrIκB effectively suppresses NF-κB signaling, alleviating liver fibrosis.
- Exosome-based therapeutics show potential for treating liver fibrosis and other chronic liver conditions.
Abstract:
Background and Aim: Biliary atresia is a rare, progressive disease that affects the bile ducts in newborns. Persistent bile duct obstruction induces various pathological conditions, including jaundice, inflammation, and liver fibrosis; however, the exact pathogenesis of biliary atresia is not yet fully understood. Nuclear factor-κB (NF-κB) is widely acknowledged as a key regulator in the pathogenesis of hepatitis and liver fibrosis, and extensive research has been conducted to develop strategies to effectively inhibit its activity to mitigate liver damage. Exosome-based therapeutic platforms offer targeted NF-κB inhibition with low immunogenicity and enhanced liver-specific delivery. This study aimed to evaluate the therapeutic efficacy of Exo-SrIκB in treating cholestatic liver fibrosis using experimental animal models. Methods: Exo-SrIκB (an exosome-based therapy containing the super-repressor IκB protein) using EXPLOR technology (Exosome engineering for Protein Loading via Optically Reversible protein-protein interactions) to encapsulate the super repressor IκB (SrIκB) within exosomes. The therapeutic efficacy of Exo-SrIκB was assessed in minipig and mouse models with experimentally induced cholestatic liver disease. Results: Administration of Exo-SrIκB significantly attenuated liver fibrosis progression in both animal models by inhibiting NF-κB nuclear translocation and reducing the expression of fibrotic markers. Treated animals exhibited reduced collagen deposition, lower α-SMA levels, and improved hepatic function compared to untreated controls. Conclusion: Exo-SrIκB effectively suppressed NF-κB signaling and alleviated liver fibrosis in experimental cholestatic liver disease models, suggesting that exosome-based therapeutics may offer a targeted and biocompatible application to managing liver fibrosis and other chronic liver diseases.
